Citations

Showing 10 of 108119 citations.

Additional Reference
Greenleaf, J.F., Ehman, Richard L.

Mayo Clinic

Science | October 22, 2021 | Volume: 270 | Issue: 5236 | Pages: 565-565

10.1126/science.270.5236.565-a Get It

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Benza, Raymond L. , Channick, Richard N. , Chin, Kelly , McLaughlin, Vallerie V. , Zamanian, Roham T. , Cravets, Matt , Bruey, Jean‐Marie, Roscigno, R.F., Mottola, David, Elman, Erin, Zisman, Lawrence S. , Ghofrani, Hossein‐Ardeschir, Chin, Kelly M , Benza, Raymond L. , Frantz, Robert P. , Channick, Richard N. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , Hemnes, Anna R. , Ghofrani, Hossein‐Ardeschir

Mayo Clinic

Pulmonary Circulation | October 22, 2021 | Volume: 11 | Issue: 4 | Pages: 1-7

10.1177/20458940211057071 | PMID 34790348 Get It

Aberrant kinase signaling that involves platelet‐derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c‐KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension. Targeting these specific pathways may potentially reverse the pathological inflammation, cellular proliferation, and fibrosis associated with pulmonary arterial hypertension progression. Seralutinib (formerly known as GB002) is a novel, potent, clinical stage inhibitor of PDGFRα/β, CSF1R, and c‐KIT delivered via inhalation that is being developed for patients with pulmonary arterial hypertension. Here, we report on an ongoing Phase 2 randomized, double‐blind, placebo‐controlled trial (NCT04456998) evaluating the efficacy and safety of seralutinib in subjects with World Health Organization Group 1 Pulmonary Hypertension who are classified as Functional Class II or III. A total of 80 subjects will be enrolled and randomized to receive either study drug or placebo for 24 weeks followed by an optional 72‐week open‐label extension study. The primary endpoint is the change from baseline to Week 24 in pulmonary vascular resistance by right heart catheterization. The secondary endpoint is the change in distance from baseline to Week 24 achieved in the 6‐min walk test. A computerized tomography sub‐study will examine the effect of seralutinib on pulmonary vascular remodelling. A separate heart rate monitoring sub‐study will examine the effect of seralutinib on cardiac effort during the 6‐min walk test.
Traf2 and NCK Interacting Kinase Is a Critical Regulator of Procollagen I Trafficking and Hepatic Fibrogenesis in Mice
Buchl, Samuel C. , Hanquier, Zachary , Haak, Andrew J. , Thomason, Yvonne M. , Huebert, Robert C. , Shah, Vijay H. , Maiers, Jessica L. , Huebert, Robert

Mayo Clinic

Hepatology Communications | October 22, 2021 | Volume: 6 | Issue: 3 | Pages: 593-609

10.1002/hep4.1835 | PMID 34677004 Get It

Hepatic fibrosis is driven by deposition of matrix proteins following liver injury. Hepatic stellate cells (HSCs) drive fibrogenesis, producing matrix proteins, including procollagen I, which matures into collagen I following secretion. Disrupting intracellular procollagen processing and trafficking causes endoplasmic reticulum stress and stress‐induced HSC apoptosis and thus is an attractive antifibrotic strategy. We designed an immunofluorescence‐based small interfering RNA (siRNA) screen to identify procollagen I trafficking regulators, hypothesizing that these proteins could serve as antifibrotic targets. A targeted siRNA screen was performed using immunofluorescence to detect changes in intracellular procollagen I. Tumor necrosis factor receptor associated factor 2 and noncatalytic region of tyrosine kinase‐interacting kinase (TNIK) was identified and interrogated in vitro and in vivo using the TNIK kinase inhibitor NCB‐0846 or RNA interference‐mediated knockdown. Our siRNA screen identified nine genes whose knockdown promoted procollagen I retention, including the serine/threonine kinase TNIK. Genetic deletion or pharmacologic inhibition of TNIK through the small molecule inhibitor NCB‐0846 disrupted procollagen I trafficking and secretion without impacting procollagen I expression. To investigate the role of TNIK in liver fibrogenesis, we analyzed human and murine livers, finding elevated TNIK expression in human cirrhotic livers and increased TNIK expression and kinase activity in both fibrotic mouse livers and activated primary human HSCs. Finally, we tested whether inhibition of TNIK kinase activity could limit fibrogenesis in vivo. Mice receiving NCB‐0846 displayed reduced CCl4‐induced fibrogenesis compared to CCl4 alone, although α‐smooth muscle actin levels were unaltered. Conclusions: Our siRNA screen effectively identified TNIK as a key kinase involved in procollagen I trafficking in vitro and hepatic fibrogenesis in vivo.
Comparison of Bleeding Profiles of Sugammadex and Neostigmine in Orthotopic Liver Transplantation
Liang, Hong , White, Launia J. , Chadha, Ryan , Renew, J. Ross

Mayo Clinic

No container title available | October 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163491381.11148574/v1 Get It

In the era of “fast-track’ liver transplantation (LT), neuromuscular blockade (NMB) antagonists such as neostigmine or sugammadex are used to achieve the restoration of neuromuscular function. While sugammadex reverses NMB faster than neostigmine, it has been shown to prolong prothrombin time (PT) and activated thromboplastin time (aPTT). However, this agent’s impact on coagulation during LT is not understood. We compare bleeding risk associated with sugammadex versus neostigmine during liver transplantation. This is a single-center, retrospective review of LT patients who received NMB antagonists intraoperatively between 01/01/2015 to 05/31/2018 at Mayo Clinic in Florida. The primary outcomes were postoperative day (POD) 0-1 bleeding events and POD 0 values of aPTT and INR. Total 241 patients were included, with 135 patients in the neostigmine group (NG) and 106 in the sugammadex group (SG). POD 0-1 postoperative bleeding requiring transfusion occurred in 20% of NG versus 10.4% in SG. POD 0-1 re-operation for bleeding occurred in 1.5% in NG vs. 0% in SG. POD 0 mean INR was 2.0±0.4 in both groups. POD 0 mean aPTT was 45.5±7.9 in NG vs. 49.3±9.0 in SG. Our retrospective study suggests that sugammadex is not associated with an increased risk of bleeding compared to neostigmine use.
Blood volume expansion, normovolemia, and clinical outcomes in chronic human heart failure: more is better
Miller, Wayne L. , Strobeck, John E., Grill, Diane E. , Mullan, Brian P., Miller, Wayne L.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | October 22, 2021 | Volume: 321 | Issue: 6 | Pages: H1074-H1082

10.1152/ajpheart.00336.2021 | PMID 34676782 Get It

The novel findings of this study demonstrate that intravascular volume profiles among the patients with chronic heart failure (HF) vary substantially even with similar clinical compensation. Importantly, a profile of blood volume (BV) expansion (compared with a normal BV) is associated with lower HF mortality/morbidity. Furthermore, RBC polycythemia is common and independently associated with improved outcomes. These observations support BV expansion with RBC polycythemia as a compensatory mechanism in chronic HF.
Impact of Multidisciplinary Team Escalating Approach on Antibiotic Stewardship in the United Arab Emirates
Sadeq, Ahmed A., Shamseddine, Jinan M., Nsutebu, Emmanuel , Moukarzel, Marleine B. , Conway, Barbara R. , Hasan, Syed Shahzad , Conlon‐Bingham, Geraldine , Aldeyab, Mamoon A. , Babiker, Zahir Osman Eltahir , Nsutebu, Emmanuel Fru, Conway, Barbara R , Hasan, Syed Shahzad , Aldeyab, Mamoon A

Mayo Clinic

Antibiotics | October 22, 2021 | Volume: 10 | Issue: 11 | Pages: 1289

10.3390/antibiotics10111289 | PMID 34827227 Get It

Antimicrobial stewardship programs (ASP) are an essential strategy to combat antimicrobial resistance. This study aimed to measure the impact of an ASP multidisciplinary team (MDT) escalating intervention on improvement of clinical, microbiological, and other measured outcomes in hospitalised adult patients from medical, intensive care, and burns units. The escalating intervention reviewed the patients’ cases in the intervention group through the clinical pharmacists in the wards and escalated complex cases to ID clinical pharmacist and ID physicians when needed, while only special cases required direct infectious disease (ID) physicians review. Both non-intervention and intervention groups were each followed up for six months. The study involved a total of 3000 patients, with 1340 (45%) representing the intervention group who received a total of 5669 interventions. In the intervention group, a significant reduction in length of hospital stay (p < 0.01), readmission (p < 0.01), and mortality rates (p < 0.01) was observed. Antibiotic use of the WHO AWaRe Reserve group decreased in the intervention group (relative rate change = 0.88). Intravenous to oral antibiotic ratio in the medical ward decreased from 4.8 to 4.1. The presented ASP MDT intervention, utilizing an escalating approach, successfully improved several clinical and other measured outcomes, demonstrating the significant contribution of clinical pharmacists atimproving antibiotic use and informing antimicrobial stewardship.
Clinical and radiographic characteristics of sacral arteriovenous fistulas: a multicenter experience
Biase, Gaetano De , Navarro, Ramón, Santos, Jaime L. Martínez , Rivas, Gabriella , Miller, David A. , Brinjikji, Waleed , Huynh, Thien J, De Biase, Gaetano , Domingo, Ricardo A. , Gupta, Vivek , Bendok, Bernard R. , Fox, W Christopher , Huynh, Thien , Tawk, Rabih G.

Mayo Clinic

Journal of Neurosurgery: Spine | October 22, 2021 | Volume: 36 | Issue: 3 | Pages: 487-497

10.3171/2021.5.spine21119 | PMID 34624835 Get It

OBJECTIVE Available data on management of sacral arteriovenous fistulas (sAVFs) are limited to individual case reports and small series. Management includes observation, endovascular embolization, or surgical ligation, with no clear guidelines on the optimal treatment modality. The authors’ objective was to report their multiinstitutional experience with management of sAVF patients, including clinical and radiographic characteristics and postprocedural outcomes. METHODS The electronic medical records of patients with a diagnosis of spinal arteriovenous fistula treated from January 2004 to December 2019 at the authors’ institutions were reviewed, and data were summarized using descriptive statistics, including percentage and count for categorical data, median as a measure of central tendency for continuous variables, and interquartile range (IQR) as a measure of dispersion. RESULTS A total of 26 patients with sAVFs were included. The median (IQR) age was 65 (57–73) years, and 73% (n = 19) of patients were male. Lower-extremity weakness was the most common presenting symptom (n = 24 [92%]), and half the patients (n = 13 [50%]) reported bowel and bladder sphincter dysfunction. The median (IQR) time from symptom onset to treatment was 12 (5.25–26.25) months. Radiographically, all patients had T2 hyperintensity at the level of the conus medullaris (CM) (n = 26 [100%]). Intradural flow voids were identified in 85% (n = 22) of patients. The majority of the lesions had a single identifiable arterial feeder (n = 19 [73%]). The fistula was located most commonly at the S1 level (n = 13 [50%]). The site where the draining vein connects to the pial venous plexus was seen predominantly at the lumbar level (n = 16 [62%]). In total, 29 procedures were performed: 10 open surgeries and 19 endovascular embolization procedures. Complete occlusion was achieved in 90% (n = 9) of patients after open surgery and 79% (n = 15) after endovascular embolization. Motor improvement was seen in 68% of patients (n = 15), and bladder and bowel function improved in 9 patients (41%). At last follow-up, 73% (n = 16) of patients had either resolution or improvement of the pretreatment intramedullary T2 signal hyperintensity. CONCLUSIONS T2 hyperintensity of the CM and a dilated filum terminale vein are consistent radiographic signs of sAVF, and delayed presentation is common. Complete occlusion was achieved in almost all patients after surgery, and endovascular embolization was effective in 70% of the patients. Further studies are needed to determine the best treatment modality based on case-specific characteristics.
Clinical Electrocardiography . pt. 1. The Arrhythmias . With an atlas of electrocardiograms. Louis N. Katz and Alfred Pick. Lea and Febiger, Philadelphia, 1956. 737 pp.
Pruitt, Raymond D.

Mayo Clinic

Science | October 22, 2021 | Volume: 124 | Issue: 3218 | Pages: 411-412

10.1126/science.124.3218.411.c Get It

Banff consensus recommendations for steatosis assessment in donor livers
Neil, Desley , Minervini, Marta I., Hübscher, Stefan G. , Brunt, Elizabeth M. , Demetris, Anthony J. , Neil, Desley A H , Smith, Maxwell L.

Mayo Clinic

Hepatology | October 22, 2021 | Volume: 75 | Issue: 4 | Pages: 1014-1025

10.1002/hep.32208 | PMID 34676901 Get It

Abstract Background and Aims No consensus criteria or approaches exist regarding assessment of steatosis in the setting of human donor liver suitability for transplantation. The Banff Working Group on Liver Allograft Pathology undertook a study to determine the consistency with which steatosis is assessed and reported in frozen sections of potential donor livers. Approach and Results A panel of 59 pathologists from 16 countries completed a questionnaire covering criteria used to assess steatosis in donor liver biopsies, including droplet size and magnification used; subsequently, steatosis severity was assessed in 18 whole slide images of donor liver frozen sections ( n = 59). Survey results (from 56/59) indicated a wide variation in definitions and approaches used to assess and report steatosis. Whole slide image assessment led to a broad range in the scores. Findings were discussed at a workshop held at the 15th Banff Conference on Allograft Pathology, September 2019. The aims of discussions were to (i) establish consensus criteria for defining “large droplet fat” (LDF) that predisposes to increased risk of initial poor graft function and (ii) develop an algorithmic approach to determine fat droplet size and the percentage of hepatocytes involved. LDF was defined as typically a single fat droplet that expands the involved hepatocyte and is larger than adjacent nonsteatotic hepatocytes. Estimating severity of steatosis involves (i) low magnification estimate of the approximate surface area of the biopsy occupied by fat, (ii) higher magnification determination of the percentage of hepatocytes within the fatty area with LDF, and (iii) final score calculation. Conclusions The proposed guidelines herein are intended to improve standardization in steatosis assessment of donor liver biopsies. The calculated percent LDF should be provided to the surgeon.
Echinococcus multilocularis in a Beef Cow from the Middle West
Magath, Thomas B.

Mayo Clinic

Science | October 22, 2021 | Volume: 147 | Issue: 3658 | Pages: 632-632

10.1126/science.147.3658.632.a Get It